Hologram Doctor-Patient Visits Launched by West Cancer Center
13 sept. 2024 09h20 HE
|
Proto
Berkeley, CA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- West Cancer Center & Research Institute and Proto Inc. announced the first holographic doctor-patient visits at UC Berkeley’s forum on Global...
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12 sept. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
11 sept. 2024 05h00 HE
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
09 sept. 2024 17h00 HE
|
Regeneron Pharmaceuticals, Inc.
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy...
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
09 sept. 2024 11h45 HE
|
Boehringer Ingelheim
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
09 sept. 2024 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab...
Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
05 sept. 2024 11h45 HE
|
Dimension Market Research
New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR...
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
05 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
05 sept. 2024 07h15 HE
|
BioNTech SE
MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom...